
Humana (HUM) Stock Forecast & Price Target
Humana (HUM) Analyst Ratings
Bulls say
Humana's financial outlook appears positive, driven by a 500 basis point improvement in Group MA margins through effective re-contracting strategies, which suggests enhanced profitability. The company is expecting robust revenue growth across multiple segments, including Specialty and Home delivery, where management anticipates that marketing cost moderation and improved risk adjustments will further boost margins over time. Additionally, the strong performance in the CenterWell segment, with a 16% revenue increase primarily from pharmacy services, highlights the firm's ability to generate significant earnings despite operational challenges, positioning Humana favorably within the competitive healthcare landscape.
Bears say
The negative outlook on Humana's stock is primarily influenced by anticipated headwinds in Medicare Advantage (MA) utilization and an increase in competition within the sector, which may adversely affect membership growth and reimbursement rates. Additionally, a decline in MA Star ratings is projected to result in a significant EPS drag of approximately $22 for 2026, further undermining the firm’s earnings outlook. Finally, decreased net investment income due to lower interest rates, combined with operational cost management challenges, may lead to sustained pressure on overall financial performance.
This aggregate rating is based on analysts' research of Humana and is not a guaranteed prediction by Public.com or investment advice.
Humana (HUM) Analyst Forecast & Price Prediction
Start investing in Humana (HUM)
Order type
Buy in
Order amount
Est. shares
0 shares